These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 21635836)

  • 1. Severe sorafenib-induced hand-foot skin reaction.
    Cuesta L; Betlloch I; Toledo F; Latorre N; Monteagudo A
    Dermatol Online J; 2011 May; 17(5):14. PubMed ID: 21635836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful topical treatment of sorafenib-induced hand-foot skin reaction in a child with hepatocellular carcinoma.
    Hütten M; Lassay L; Sachs B; Deutz P; Mertens R; Baron JM; Merk HF; Ott H
    Pediatr Dermatol; 2009; 26(3):349-50. PubMed ID: 19706105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy.
    Yang CH; Lin WC; Chuang CK; Chang YC; Pang ST; Lin YC; Kuo TT; Hsieh JJ; Chang JW
    Br J Dermatol; 2008 Mar; 158(3):592-6. PubMed ID: 18070211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interstitial granulomatous drug reaction to sorafenib.
    Martínez-Morán C; Nájera L; Ruiz-Casado AI; Romero-Maté A; Espinosa P; Meseguer-Yebra C; Córdoba S; Borbujo JM
    Arch Dermatol; 2011 Sep; 147(9):1118-9. PubMed ID: 21931061
    [No Abstract]   [Full Text] [Related]  

  • 5. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor.
    Autier J; Escudier B; Wechsler J; Spatz A; Robert C
    Arch Dermatol; 2008 Jul; 144(7):886-92. PubMed ID: 18645140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perforating folliculitis, angioedema, hand-foot syndrome--multiple cutaneous side effects in a patient treated with sorafenib.
    Wolber C; Udvardi A; Tatzreiter G; Schneeberger A; Volc-Platzer B
    J Dtsch Dermatol Ges; 2009 May; 7(5):449-52. PubMed ID: 19178612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sorafenib-induced psoriasiform eruption in a patient with metastatic thyroid carcinoma.
    Diamantis ML; Chon SY
    J Drugs Dermatol; 2010 Feb; 9(2):169-71. PubMed ID: 20214183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Palmoplantar cutaneous reaction to sorafenib].
    Echeverría B; Llombart B; Botella-Estrada R; Guillén C
    Actas Dermosifiliogr; 2009 Oct; 100(8):736-7. PubMed ID: 19775561
    [No Abstract]   [Full Text] [Related]  

  • 9. Sorafenib for recurrent hepatocellular carcinoma after liver transplantation.
    Yoon DH; Ryoo BY; Ryu MH; Lee SG; Hwang S; Suh DJ; Lee HC; Kim TW; Ahn CS; Kim KH; Moon DB; Kang YK
    Jpn J Clin Oncol; 2010 Aug; 40(8):768-73. PubMed ID: 20494947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
    Lee WJ; Lee JL; Chang SE; Lee MW; Kang YK; Choi JH; Moon KC; Koh JK
    Br J Dermatol; 2009 Nov; 161(5):1045-51. PubMed ID: 19558553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sorafenib: a promising new targeted therapy for renal cell carcinoma.
    Wood LS; Manchen B
    Clin J Oncol Nurs; 2007 Oct; 11(5):649-56. PubMed ID: 17962173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib.
    McLellan B; Kerr H
    Dermatol Ther; 2011; 24(4):396-400. PubMed ID: 21910797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.
    Wörns MA; Weinmann A; Pfingst K; Schulte-Sasse C; Messow CM; Schulze-Bergkamen H; Teufel A; Schuchmann M; Kanzler S; Düber C; Otto G; Galle PR
    J Clin Gastroenterol; 2009; 43(5):489-95. PubMed ID: 19247201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib.
    Lacouture ME; Reilly LM; Gerami P; Guitart J
    Ann Oncol; 2008 Nov; 19(11):1955-61. PubMed ID: 18550575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sorafenib-associated hand-foot syndrome in Japanese patients.
    Iijima M; Fukino K; Adachi M; Tsukamoto T; Murai M; Naito S; Minami H; Furuse J; Akaza H
    J Dermatol; 2011 Mar; 38(3):261-6. PubMed ID: 21342228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High toxicity of sorafenib for recurrent hepatocellular carcinoma after liver transplantation.
    Staufer K; Fischer L; Seegers B; Vettorazzi E; Nashan B; Sterneck M
    Transpl Int; 2012 Nov; 25(11):1158-64. PubMed ID: 22882364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
    Abou-Alfa GK; Schwartz L; Ricci S; Amadori D; Santoro A; Figer A; De Greve J; Douillard JY; Lathia C; Schwartz B; Taylor I; Moscovici M; Saltz LB
    J Clin Oncol; 2006 Sep; 24(26):4293-300. PubMed ID: 16908937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: recommendations from a European nursing task group.
    Edmonds K; Hull D; Spencer-Shaw A; Koldenhof J; Chrysou M; Boers-Doets C; Molassiotis A
    Eur J Oncol Nurs; 2012 Apr; 16(2):172-84. PubMed ID: 21641280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Localized dyskeratotic plaque with milia associated with sorafenib.
    Chappell JA; Burkemper NM; Semchyshyn N
    J Drugs Dermatol; 2009 Jun; 8(6):573-6. PubMed ID: 19537383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Hand-foot syndrome and sorafenib].
    Milano G; Mortier L; Digue L; Desmedt E; Ravaud A
    Bull Cancer; 2009 Feb; 96(2):191-7. PubMed ID: 19258226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.